Christopher Peetz Sells 9,102 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the sale, the chief executive officer now directly owns 115,920 shares of the company’s stock, valued at approximately $5,589,662.40. This represents a 7.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Stock Up 4.1 %

MIRM opened at $52.28 on Thursday. The company has a market capitalization of $2.51 billion, a PE ratio of -25.88 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $53.49. The business has a 50-day moving average of $44.49 and a 200-day moving average of $42.10.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) earnings per share. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of MIRM. Lord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals during the third quarter worth $28,913,000. Loomis Sayles & Co. L P acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $19,473,000. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $10,136,000. Finally, Frazier Life Sciences Management L.P. boosted its position in Mirum Pharmaceuticals by 1.2% during the third quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock worth $256,245,000 after purchasing an additional 75,000 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Leerink Partners upped their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Citigroup lifted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.